NO | สินค้า | Cas no | ตัวบ่งชี้คุณภาพคีย์ | |||
ความบริสุทธิ์ | สูงสุด ความไม่ดี | ตัวทำละลายทั้งหมดตกค้าง | ความชื้น | |||
1 | FMOC-β-Ala-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
2 | FMOC-D-Ala-D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
3 | FMOC-β-Ala-D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
4 | fmoc-arg (PBF) -Arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
5 | FMOC-β-Ala-Arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
6 | FMOC-D-Arg (PBF) -D-Arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
7 | FMOC-β-Ala-D-Arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
8 | fmoc-homoarg (pbf) -homoarg (pbf) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
9 | FMOC-β-Ala-Homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
10 | fmoc-asn (trt) -asn (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
11 | FMOC-β-Ala-ASN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
12 | fmoc-asp (otbu) -asp (otbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
13 | FMOC-β-Ala-Asp (OTBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
14 | fmoc-cys (trt) -cys (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
15 | FMOC-β-Ala-Cys (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
16 | fmoc-cys (acm) -cys (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
17 | FMOC-β-Ala-Cys (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
18 | fmoc-gln (trt) -gln (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
19 | FMOC-β-Ala-gln (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
20 | fmoc-glu (otbu) -glu (otbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
21 | fmoc-β-ala-glu (otbu) -oh.h2o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
22 | fmoc-β-ala-gly-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
23 | fmoc-his (trt) -His (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
24 | FMOC-β-Ala-His (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
25 | fmoc-ile-oh-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
26 | FMOC-β-Ala-Ile-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
27 | fmoc-leu-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
28 | fmoc-β-ala-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
29 | FMOC-D-LEU-D-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
30 | FMOC-β-Ala-D-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
31 | fmoc-lys (BOC) -Lys (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
32 | FMOC-β-Ala-Lys (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
33 | fmoc-lys (alloc) -lys (alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
34 | fmoc-β-ala-lys (alloc) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
35 | fmoc-met-met-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
36 | FMOC-β-Ala-Met-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
37 | fmoc-orn (boc) -orn (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
38 | fmoc-β-ala-orn (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
39 | fmoc-phe-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
40 | fmoc-β-ala-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
41 | FMOC-D-PHE-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
42 | fmoc-β-ala-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
43 | fmoc-pro-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
44 | FMOC-β-Ala-Pro-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
45 | fmoc-ser (tbu) -ser (tbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
46 | FMOC-β-Ala-Ser (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
47 | fmoc-ser (trt) -ser (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
48 | FMOC-β-Ala-Ser (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
49 | fmoc-thr (tbu) -thr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
50 | FMOC-β-Ala-Thr (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
51 | fmoc-trp (boc) -trp (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
52 | fmoc-β-ala-trp (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
54 | FMOC-β-Ala-D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
55 | fmoc-tyr (tbu) -tyr (tbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
56 | FMOC-β-Ala-Tyr (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
57 | FMOC-D-TYR (ET) -D-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
58 | FMOC-β-Ala-D-Tyr (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
59 | fmoc-tyr (me) -tyr (me) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
60 | fmoc-β-ala-tyr (me) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
61 | fmoc-val-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
62 | FMOC-β-Ala-Val-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
64 | FMOC-β-Ala-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
65 | fmoc-β-ala-dab-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
66 | fmoc- (3- (2-naphthyl) -d-Ala) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
67 | FMOC-β-Ala-3- (2-naphthyl) -D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
68 | fmoc- (3- (3-pyridinyl) -d-Ala) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
69 | FMOC-β-Ala-3- (3-pyridinyl) -d-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
70 | fmoc- (4-chloro-d-phe) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
71 | fmoc-β-Ala-4-chloro-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
72 | fmoc- (d-4aph (tbucbm)) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
73 | FMOC-β-Ala-D-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
74 | fmoc-aph (l-hor) -aph (l-hor) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
75 | fmoc-β-ala-aph (l-hor) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
76 | fmoc-lys (ipr, boc) -lys (ipr, boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
77 | FMOC-β-Ala-Lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
78 | fmoc-β-ala-eea-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
79 | fmoc-aib-aib-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
80 | fmoc-β-ala-aib-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
81 | fmoc-arg-oh | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
82 | H-Arg (PBF) -OH | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
83 | FMOC-D-Arg-Oh | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
84 | HD-Arg (PBF) -OH | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
85 | fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
86 | H-Homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
87 | fmoc-d-homoarg-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
88 | HD-HOMOARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
89 | fmoc-asn-oh | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
90 | H-ASN (TRT) -OH | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
91 | fmoc-asp-oh | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
92 | h-asp (otbu) -oh | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
93 | fmoc-cys-oh | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
94 | H-Cys (TRT) -OH | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
95 | H-cys (ACM) -OH.HCL | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
96 | fmoc-gln-oh | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
97 | h-gln (trt) -oh | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
98 | fmoc-glu-oh | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
99 | h-glu (otbu) -oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
100 | fmoc-his-oh | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
101 | H-HIS (TRT) -OH | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
102 | Boc-his-oh | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
103 | fmoc-lys-oh | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
104 | H-lys (BOC) -OH | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
105 | H-lys (alloc) -OH | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
106 | fmoc-orn-oh.hcl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
107 | h-orn (boc) -oh | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
108 | fmoc-ser-oh | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
109 | H-Ser (TBU) -OH | 2425-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
110 | H-Ser (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
111 | fmoc-thr-oh.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
112 | h-trh (tbu) -oh | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
113 | fmoc-trp-oh | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
114 | H-TRP (BOC) -OH | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
115 | FMOC-D-TRP-OH | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
117 | fmoc-tyr-oh | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
118 | H-tyr (tbu) -OH | 2425-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
119 | fmoc-d-tyr-oh | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
120 | HD-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
121 | h-tyr (me) -oh.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
123 | HD-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
124 | fmoc-lys (ipr) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
125 | H-lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
ค่าตอบแทน
Gentolex จัดหาผลิตภัณฑ์ที่มีคุณภาพดีหากลูกค้ามีคุณภาพของผลิตภัณฑ์ใด ๆ ที่เพิ่มขึ้นภายในกรอบเวลาที่กำหนดด้วยหลักฐานที่เพียงพอเราจะให้การวิเคราะห์และการประเมินผลที่จำเป็นเพื่อกระตุ้นขั้นตอนการชดเชย
การผลิต
ความสามารถของผลิตภัณฑ์ยาถึงเกรดตันความสามารถของผลิตภัณฑ์เคมีถึง 100 ตัน+ เกรดความสามารถมีความพร้อมในการให้บริการลูกค้าทั่วโลก
การวิจัยและพัฒนา
ทุกปีมีการจัดทำแผนโดยทีม R&D เพื่อพัฒนาผลิตภัณฑ์ใหม่ที่แตกต่างกันเมื่อตั้งเป้าหมายสมาชิกทุกคนในทีมจะต้องดำเนินการต่อด้วยความรับผิดชอบของ KPI และด้วยนโยบายแรงจูงใจ